All In Biotech

Drug Trial Radar · NCT06853431

Determination of ED50 and ED95 With Clinical Efficacy of Intranasal Dexmedetomidine Combined With Esketamine for Preoperative Sedation in Pediatric General Anesthesia

Last checked: Nov 20, 2026Latest source record: Dec 2, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Mar 1, 2025

Primary completion

Nov 30, 2025

Study completion Nov 30, 2025

Sponsor

Lead sponsor
Second Affiliated Hospital of Wenzhou Medical UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Mar 3, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Sequential
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 months, up to 72 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

For pediatric patients undergoing general anesthesia, poor anesthesia induction compliance often has adverse effects on individual behavior in the early postoperative period. Dexmedetomidine can reduce the cardiovascular responses and postoperative mental adverse reactions caused by esketamine anesthesia induction \[6\]. This study aims to explore the ED50 and ED95 and clinical effects of the combination of dexmedetomidine and esketamine nasal drops for preoperative sedation in children of different ages undergoing general anesthesia, providing a theoretical basis for the combined use of dexmedetomidine and esketamine for preoperative sedation in children undergoing general anesthesia.

Conditions

  • Preoperative Anxiety
  • Preoperative Sedation
  • Children
  • Dexmedetomidine
  • Esketamine
  • ED95
  • ED50
  • Preoperative Sedation of Children

Interventions

  • dexmedetomidineDrug

    esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.

  • EsketamineDrug

    esketamine 0.5mg/kg intranasally via a nasal dropper, dexmedetomidine 1μg/kg was given intranasally, and the adjusted dose of dexmedetomidine was 0.25μg/kg.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Onset time of sedationTime frame: Within 30 minutes after intranasal administration of dexmedetomidine.

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Not yet recruiting

  • The second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University

    Wenzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.